Rollins Financial’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Rollins Financial’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,717	Closed	-$304K	–	126
2021 Q4	$304K	Buy	+2,717	New	+$328K	0.09%	89
2021 Q2	$1.2M	Buy	8,826 +939	+12%	+$123K	0.44%	33
2021 Q1	$1.07M	Sell	7,887 -25	-0.3%	-$3.74K	0.46%	30
2020 Q4	$1.11M	Buy	+7,912	New	+$1.01M	0.51%	26

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Rollins Financial's XBI Position: Q1 2022 in Review

Rollins Financial sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 2,717 shares — an estimated $304K sold.

Rollins Financial first reported a position in XBI in Q4 2020 and held it in 4 quarters. The position peaked at $1.2M in Q2 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Rollins Financial reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Rollins Financial sold 2,717 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $304K.
Rollins Financial first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 4 quarters.
Rollins Financial's State Street SPDR S&P Biotech ETF position peaked at $1.2M in Q2 2021.
703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Rollins Financial's 13F filing for Q1 2022, filed 4 May 2022.